Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2008; 29(03): 10-13
DOI: 10.4103/0971-5851.51415
Original Article

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma

Deepak Dabkara
Department of Medical Oncology, Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi 110029, India
,
Jyoti Bajpai
Department of Medical Oncology, Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi 110029, India
› Author Affiliations
› Further Information
Also available at
  PDF Download Permissions and Reprints


Publication History

Article published online:
02 March 2022

© 2008. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Kumar L, Vikram P& Kochupillai V. Multiple myeloma: Recent advances in management. Nat Med J India 2006;19:80-89.
  • 2 Dimopoulos M, , SpencerA, Attal M, et al. Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma. for the Multiple Myeloma (010) Study Investigators. New Eng J Med 2007;357:2123-2132 .
  • 3 Blade J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high dose therapy and haemopoietic stem cell transplantation. Br J Haematol 1998;102:1115-23.
  • 4 Durie BGM, Salmon SE. A clinical staging system for multiple myeloma : correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival. Cancer 1975;36:842.
  • 5 Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. NEJM 1999;341:1565-71
  • 6 Rajkumar SV, Hayman S, Gertz MA et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 2002;20:4319-23.
  • 7 Richardson P, Jagannath S, Schlossman R, et al. A multicenter randomized phase II study to evaluate the efficacy and safety of two CC-5013 dose regimens, when used alone or in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma. Blood 2002;100:104a(abst).
  • 8 Weber DM , Chen C, Niesvizky R, et al. for the Multiple Myeloma (009)Study Investigators. Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America. New Eng J Med 2007;357:2133-42.
  • 9 Rajkumar V,Jacobus S Callender N et al .A randomized phase III trial of lenalidomide plus high dose dexamethasone versus low dose dexamethasone in newly diagnosed multiple myeloma(E4A03) A trial coordinated by Eastern Cooperative Oncology Group.Blood 2006:08(abstr 798).